Press Release|

SHL Medical and Grand River Aseptic Manufacturing forge strategic partnership to offer fill finish services for RTU cartridge used in Maggie 5.0® autoinjector

20240917 Alliance Gram External Website Inside Article – 9
SHL Medical has announced a strategic partnership with Grand River Aseptic Manufacturing

SHL Medical, a world-leading solutions provider of advanced drug delivery systems such as autoinjectors, pen injectors, and innovative specialty delivery systems has announced a strategic partnership with Grand River Aseptic Manufacturing (GRAM), a highly regarded contract development and manufacturing organization (CDMO) specializing in sterile injectable biologics and scalable pharmaceutical manufacturing solutions tailored to diverse client needs. The collaboration aims to introduce fill-finish services for the RTU cartridge used in Maggie® 5.0 autoinjector.

The Maggie® 5.0 mL, an extension of SHL’s cartridge-based 3.0 mL Maggie autoinjector, is designed for large-volume drug delivery. Equipped with SHL’s proven Needle Isolation Technology (NIT®), this 2-step autoinjector features a permanently concealed needle, removing the need for patients to manually attach the needle before each use, thereby enhancing ease of use and safety.

GRAM brings significant experience in aseptic fill-finish to their partners. GRAM’s drive to improve patient care and increase collaboration on drug delivery devices will greatly benefit pharmaceutical clients through this partnership.

The partnership allows SHL Medical and GRAM to offer pharmaceutical companies an integrated solution for large volume autoinjectors combining SHL’s expertise in developing and manufacturing innovative drug delivery solutions and GRAM’s unique experience with filling large volume containers. Pharmaceutical organizations can now benefit from an established supply chain and faster market entry for the Maggie® 5.0 autoinjector.

Markus Puusepp, SHL Medical’s Chief Growth Officer, commented on the collaboration: “The partnership with GRAM underlines our commitment to providing comprehensive solutions that address the growing needs of our pharmaceutical partners. By combining SHL’s innovative drug delivery systems with GRAM’s expertise in aseptic fill-finish, we are well-positioned to bring effective solutions to market more efficiently, benefiting both our partners and the patients they serve.”

Dave Powell, Vice President of Business Development at Grand River Aseptic Manufacturing, added: “We are thrilled to partner with SHL Medical to support the Maggie® 5.0 autoinjector. This partnership supports GRAM’s vision of being recognized as a CDMO leader in both fill and finish services and drug delivery solutions. Our patient-centered culture and dedication to our partner’s success align perfectly with SHL’s dedication to innovation in drug delivery. Together, we are creating a streamlined solution that will offer significant value to pharmaceutical companies and, ultimately, patients.”

 

About Grand River Aseptic Manufacturing, Inc.

Grand River Aseptic Manufacturing, Inc., a prominent aseptic fill-finish contract development and manufacturing organization, delivers biologics, small molecules, and vaccine capabilities for liquid and lyophilized vials, syringes, and cartridges. Grand River Aseptic Manufacturing’s 450,000 sq. ft. of sophisticated GMP space supports customers’ drug products with advanced equipment, innovative technology, and a breadth of experienced team members.

For additional information, visit https://www.grandriverasepticmfg.com/

About SHL Medical

As a world-leading solutions provider of advanced drug delivery systems, SHL Medical is the partner of choice for many leading pharma and biotech companies. Driven by our company purpose – Enabling Patients’ Independence – we offer patient-centric solutions for the design, development, and manufacturing of autoinjectors, pen injectors, as well as innovative specialty delivery systems for large-volume and high-viscosity formulations. We also offer final assembly, labeling, and packaging solutions for our drug delivery systems.  ​

In response to the rising trend in home therapy, SHL has increased developmental work in the digital healthcare sector to help improve the drug delivery ecosystem

Located across Switzerland, Taiwan, Sweden, and the US, our global team of experts collaborate seamlessly as one team in utilizing our comprehensive in-house manufacturing capabilities. Our solutions offer customization and optimization for each project while proactively weaving sustainability-driven measures into our designs and processes to contribute to a cleaner earth.​

For additional information, visit www.shl-medical.com

Media contact: info@shl-medical.com

Share:

Related News